The clinical utility of EGFR mutation profiling in hepatocellular carcinoma (HCC) is challenged by its exceptionally low mutation frequency (~2%) and a high degree of spatial intratumoral heterogeneity (ITH), reported to range from 5.21% to 88.27% (38, 39). The gene discussed is EGFR; the disease is hepatocellular carcinoma.